In prostate cancer, for example, ELF5 has been shown to inhibit transforming growth factor (TGF)-β-driven epithelial–mesenchymal transition by blocking phosphorylation of the TGF-β effector protein SMAD3 [17]. Here, ELF5 is linked to prostate cancer.